Medical gauze

Abstract

To provide a medical gauze capable of increasing an amount of bacterial attachment.SOLUTION: A medical gauze according to an embodiment includes a gauze body and a cello-oligosaccharide having, at the anomeric position of a reducing end, a substituent containing an amino group, the cello-oligosaccharide being immobilized on the gauze body.SELECTED DRAWING: Figure 3

Description

[Technical Field]

[0001] The present invention relates to medical gauze. [Background technology]

[0002] Medical gauze is used in wound treatment and surgery to control bleeding, absorb body fluids, protect from trauma, etc. Here, gauze is generally made of coarse, soft cotton cloth, but is not limited to this and may also be made of non-woven fabrics such as non-woven gauze.

[0003] It is known that crystalline cellulose can be artificially synthesized. The cellulose obtained by artificial synthesis is generally an oligomer called cellooligosaccharide. Patent Document 1 discloses cellooligosaccharides in which a substituent containing an amino group has been introduced at the anomeric position of the reducing end, and proposes that aggregates of such cellooligosaccharides be used as scaffolding materials for cell culture in which animal cells are grown, films, battery separators, and the like. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Japanese Patent Application Publication No. 2018-174871 Summary of the Invention [Problem to be solved by the invention]

[0005] While investigating new uses for the cellooligosaccharides, the present inventors discovered that immobilizing cellooligosaccharides on gauze increases the amount of bacteria that adheres to it.

[0006] The embodiments of the present invention have been made in view of the above points, and have an object to provide medical gauze that can increase the amount of bacteria attached. [Means for solving the problem]

[0007] The present invention includes the embodiments shown below. [1] A medical gauze comprising a gauze body and a cellooligosaccharide having an amino group-containing substituent at the anomeric position of the reducing end and immobilized on the gauze body. [2] The cellooligosaccharide is represented by the following general formula (1): [ka] In the formula, n represents an average degree of polymerization and is a number of 5 to 20, and A represents a divalent hydrocarbon group having 1 to 20 carbon atoms. [1] The medical gauze according to [1]. [3] A medical gauze according to [1] or [2], in which the cellooligosaccharide is immobilized on the gauze body by precipitating it in the presence of the gauze body. [4] The medical gauze according to any one of [1] to [3], which is used to cover a wound surface. [Effects of the Invention]

[0008] According to an embodiment of the present invention, the amount of bacteria attached can be increased by immobilizing cellooligosaccharides having a substituent containing an amino group on the gauze body. [Brief explanation of the drawings]

[0009] [Figure 1] Cross-sectional schematic diagram of cellooligosaccharide aggregates. [Figure 2] Conceptual diagram of a cellulose nanosheet, an example of a cellooligosaccharide assembly. [Figure 3] Fluorescence microscopy images showing the results of bacterial adhesion in Test Example 1, where (A) is an image showing the bacterial adhesion state for the CEL-NH2 composite gauze (immobilized by phosphoric acid precipitation) of Example 1, (B) is an image showing the bacterial adhesion state for the CEL-NH2 composite gauze (immobilized by neutralization-induced precipitation) of Example 2, and (C) is an image showing the bacterial adhesion state for the uncomposite gauze. [Figure 4] Scanning electron microscope (SEM) image of the CEL-C6 composite gauze of Example 1. [Figure 5] Scanning electron microscope (SEM) image of the CEL-C6 composite gauze of Example 2. [Figure 6] Graphs showing the quantitative results of bacterial adhesion in Test Example 2, where (A) is a graph showing the results for the CEL-NH2 composite gauze (phosphate precipitation fixation) of Example 3, and (B) is a graph showing the results for the CEL-NH2 composite gauze (neutralization-induced precipitation fixation) of Example 4. DETAILED DESCRIPTION OF THE INVENTION

[0010] The medical gauze according to this embodiment (hereinafter simply referred to as "gauze") comprises a gauze body and a cellooligosaccharide having a substituent containing an amino group at the anomeric position of the reducing end and immobilized on the gauze body.

[0011] In this specification, the gauze body is not limited to cotton fabric in the strict sense of the term, but may be a woven fabric, knitted fabric, or nonwoven fabric. Furthermore, the material is not limited to cotton, but may be other cellulose fibers such as hemp, natural fibers other than cellulose fibers, or synthetic fibers such as polyester fibers. Preferably, the gauze body is primarily made of cellulose fibers, for example, containing 50% by mass or more of cellulose fibers, more preferably made of cellulose fibers, and even more preferably made of cotton. Ordinary coarse, soft cotton fabric may also be used.

[0012] Cellooligosaccharides are oligosaccharides with a structure in which glucose units are linked by β-1,4-glycosidic bonds, and are also called cellulose oligomers. In this embodiment, a cellooligosaccharide in which a substituent containing an amino group is introduced at the anomeric position of the reducing end (hereinafter, also referred to as "aminated cellooligosaccharide") is used. The amino group is preferably a primary amino group.

[0013] Immobilization of aminated cellooligosaccharides on the fiber surface of the gauze itself increases the amount of bacteria adhering to the gauze. The reason for this is thought to be, but not limited to, the following: The amino groups introduced at the anomeric positions of aminated cellooligosaccharides are positively charged by protonation, which causes the gauze surface to be positively charged by the aminated cellooligosaccharides. Therefore, bacteria with negatively charged cell surfaces are more likely to be adsorbed by electrostatic interactions, which is thought to increase the amount of bacteria adhering to the gauze. This increased bacterial adhesion to the gauze can reduce bacterial adhesion to the wound surface and inhibit bacterial proliferation on the wound surface.

[0014] Furthermore, when aminated cellooligosaccharides are immobilized on gauze, the amount of bacteria attached increases compared to uncomplexed gauze without immobilized cellooligosaccharides, regardless of whether serum is present or absent, and therefore, the amount of bacteria on the wound surface can be reduced not only in the early stage of wound healing but also in the late stage when the wound surface is almost dry.

[0015] The average degree of polymerization (DP) of aminated cellooligosaccharides (the average number of glucose units present in one molecule) is not particularly limited, but is preferably 5 to 20. The average degree of polymerization (DP) is more preferably 6 to 16, more preferably 6 to 10, and even more preferably 7 to 10. The average degree of polymerization of aminated cellooligosaccharides is a weighted average of the degrees of polymerization according to the mass ratio of aminated cellooligosaccharides. Aminated cellooligosaccharides are usually a mixture of compounds with different degrees of polymerization, and may include, for example, those with a degree of polymerization of 4 to 20, or those with a degree of polymerization of 5 to 18.

[0016] As the aminated cellooligosaccharide, it is preferable to use a compound represented by the following general formula (1). [ka]

[0017] In formula (1), a substituent (-A-NH2) containing an amino group is bonded via an oxygen atom to the anomeric position, i.e., the carbon at position 1 (anomeric carbon) of the reducing end. The wavy line in the bond between the anomeric carbon and the OA-NH2 group in formula (1) indicates that the configuration of the OA-NH2 group is α, β, or a mixture of α and β. The configuration of the OA-NH2 group is preferably β.

[0018] In formula (1), n ​​represents the average degree of polymerization of cellooligosaccharides, and is preferably 5-20, more preferably 6-16, more preferably 6-10, and even more preferably 7-10, as described above.

[0019] In formula (1), A represents a divalent hydrocarbon group having 1 to 20 carbon atoms. A may be a divalent aliphatic hydrocarbon group or a divalent aromatic hydrocarbon group. Examples of the divalent aliphatic hydrocarbon group include an alkanediyl group and an alkenediyl group, and the group may have a straight chain or a branched chain. Examples of the divalent aromatic hydrocarbon group include a divalent aliphatic hydrocarbon group having an aromatic ring substituent and an arenediyl group, and the aromatic ring may be added with a substituent such as an alkyl group. The number of carbon atoms in A is preferably 1 to 10, and more preferably 1 to 5. A is preferably an alkanediyl group having 1 to 10 carbon atoms, and more preferably an alkanediyl group having 1 to 5 carbon atoms.

[0020] The method for preparing aminated cellooligosaccharides is not particularly limited. For example, aminated cellooligosaccharides may be prepared by an enzymatic synthesis reaction utilizing the reverse reaction of cellodextrin phosphorylase (CDP) (see Y. Yataka et al., Langmuir, 2016, 32, 10120-10125).

[0021] For example, when aminated cellooligosaccharides in which A is an alkanediyl group are prepared by enzymatic synthesis, α-glucose-1-phosphate (αG1P) and an aminoalkyl-β-D-glucopyranoside are reacted with CDP, whereby αG1P is sequentially polymerized as a monomer with the aminoalkyl-β-D-glucopyranoside as a primer, to obtain the aminated cellooligosaccharide represented by formula (1).

[0022] CDP is known to be produced by microorganisms such as Clostridium thermocellum and Cellulomonas, and can be obtained by known methods using these microorganisms. For example, CDP derived from Clostridium thermocellum YM4 can be prepared in an Escherichia coli expression system according to the method described in M. Krishnareddy et al., J. Appl. Glycosci., 2002, 49, 1-8, but is not limited thereto.

[0023] The concentration of CDP is not particularly limited and may be, for example, 0.1 U / mL or more, or 0.2 U / mL or more. Here, the amount of CDP enzyme can be determined, for example, based on the enzyme activity. For example, αG1P, D-(+)-cellobiose, and CDP are incubated, the amount of phosphate produced by CDP is quantified, and the amount of enzyme that liberates 1 μmol of phosphate per minute can be defined as 1 U.

[0024] For example, aminated cellooligosaccharides of formula (1) can be synthesized by mixing 10-1000 mM αG1P, 10-200 mM aminoalkyl-β-D-glucoside, and 0.1 U / mL or more of CDP in 100-1000 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES) buffer (pH 7.0-8.0) and incubating the mixture at 10-80°C for 30 minutes to 30 days. Here, "M" stands for molar concentration (mol / L), and therefore "mM" stands for "mmol / L."

[0025] The aminated cellooligosaccharides may be immobilized (complexed) to the gauze body as self-assembled aggregates. Preferably, the aminated cellooligosaccharides are immobilized to the gauze body by precipitation in the presence of the gauze body. The aminated cellooligosaccharides immobilized in this manner are cellooligosaccharide aggregates having the crystalline structure of cellulose type I (type 1) or cellulose type II (type 2), preferably aggregates having the crystalline structure of cellulose type II.

[0026] The crystalline structure of cellulose type I is similar to that of naturally occurring cellulose, in that adjacent chains are oriented in the same direction, whereas the crystalline structure of cellulose type II is such that adjacent chains are oriented in opposite directions.

[0027] Specifically, aminated cellooligosaccharides are represented by arrows pointing from the reducing end to the non-reducing end of the cellulose chain, and substituents containing amino groups are represented by wavy lines, as shown below in formula (1). In the crystalline structure of cellulose type II, aminated cellooligosaccharides are arranged so that the arrows point alternately between adjacent molecular chains, as shown in Figure 1.

[0028] In one embodiment, the cellooligosaccharide aggregate having the cellulose type II crystal structure may have a sheet-like structure (cellulose nanosheet) consisting of a monolayer, as shown in FIG. 2. Here, the sheet-like structure is a concept that encompasses ribbon-like structures (cellulose nanoribbons) as shown in FIG. 2. Such nanoribbons may be precipitated in spikes on the fiber surface of the gauze body and fixed so as to cover the fiber surface of the gauze body (see FIG. 4). Alternatively, the nanoribbons may be precipitated in a network-like structure (also called a hairy structure) on the fiber surface of the gauze body and fixed so as to cover the fiber surface of the gauze body (see FIG. 5).

[0029] The method for immobilizing aminated cellooligosaccharides as cellooligosaccharide aggregates on the gauze bodies by precipitating them in the presence of the gauze bodies is not particularly limited. For example, aminated cellooligosaccharides may be obtained by the above-mentioned enzymatic synthesis reaction and then incubated in the presence of the gauze bodies to precipitate the cellooligosaccharide aggregates and immobilize them on the gauze bodies. Alternatively, aminated cellooligosaccharides obtained by the enzymatic synthesis reaction may be dissolved in alkali and then neutralized with acid to precipitate the cellooligosaccharide aggregates in the presence of the gauze bodies and immobilize them on the gauze bodies (hereinafter, this immobilization method is referred to as neutralization-induced precipitation immobilization). Alternatively, aminated cellooligosaccharides obtained by the enzymatic synthesis reaction may be dissolved in phosphoric acid and then water may be added to precipitate the cellooligosaccharide aggregates in the presence of the gauze bodies and immobilize them on the gauze bodies (hereinafter, this immobilization method is referred to as phosphoric acid precipitation immobilization).

[0030] In the medical gauze according to this embodiment, the amount of aminated cellooligosaccharide immobilized on the gauze body is not particularly limited, and is preferably 0.1 to 200 parts by mass, more preferably 1 to 50 parts by mass, and even more preferably 5 to 20 parts by mass, per 100 parts by mass of the gauze body.

[0031] The medical gauze according to this embodiment may be composed of only the gauze body and aminated cellooligosaccharides, but may also contain, for example, an antibacterial agent or silver nanoparticles, as long as the effect is not impaired.

[0032] The medical gauze according to this embodiment can be used in wound treatment and surgery, for example, to suppress bleeding, absorb body fluids, and protect from trauma. It is preferably used to cover the wound surface, and is used as a wound dressing for suppressing bleeding from the wound surface and protecting the wound surface, for example, as a bandage pad. Alternatively, the medical gauze can be used, for example, as a mask.

[0033] The medical gauze according to this embodiment has excellent bacterial adhesion properties, so it can adsorb bacteria from the wound surface and suppress bacterial proliferation on the wound surface. Furthermore, as described above, the amount of bacteria adhered to the gauze increases not only in the presence of serum but also in the absence of serum, compared to uncomplexed gauze. Therefore, the amount of bacteria on the wound surface can be reduced not only in the early stage of the wound but also in the late stage when the wound surface is almost dry. [Example]

[0034] The present invention will be further explained below with reference to examples, but is not limited to these.

[0035] [Synthesis of aminated cellooligosaccharides] According to the method described in T. Nohara et al., J. Biomater. Sci., Polym. Ed., 2017, 28, 925-938, enzyme-catalyzed polymerization was carried out according to the following reaction scheme to synthesize aminated cellooligosaccharides with an average degree of polymerization of 10 (n = 10). [ka]

[0036] Specifically, 200 mmol / L αG1P, 50 mmol / L 2-aminoethyl-β-D-glucopyranoside, and 0.2 U / mL cellodextrin phosphorylase (CDP) were mixed in 500 mmol / L 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES) buffer (pH 7.5) and incubated at 60°C for 3 days. The reaction mixture containing the product was centrifuged (15,000 rpm, 10 minutes or more, 4°C). The supernatant was removed, and the product was redispersed in ultrapure water. This procedure was repeated under the same conditions to obtain aminated cellooligosaccharides (CEL-NH2). The supernatant was then purified to a substitution rate of 99.999% or higher.

[0037] The average degree of polymerization of cellooligosaccharides was measured using a proton nuclear magnetic resonance (NMR) spectrometer. Specifically, 12 mg or more of the freeze-dried product was dissolved in 600 μL of 4% by mass sodium deuterium hydroxide deuterium oxide solution to prepare a measurement sample. The NMR spectrometer used was an ADVANCE III HD500 (Bruker Biospin, magnetic field strength: 500 MHz, number of accumulations: 16). The average degree of polymerization was calculated based on the integral values ​​of the protons at the anomeric position of the reducing end of the cellooligosaccharide and at other anomeric positions.

[0038] [Test Example 1] (Example 1: CEL-NH2 composite gauze (immobilized by precipitation of phosphoric acid)) ·Complexation of gauze with cellooligosaccharides: Lyophilized aminated cellooligosaccharides (CEL-NH2) were dissolved in an 85% by mass aqueous solution of phosphoric acid to a concentration of 2% (w / v). 30 μL of the resulting solution and 30 μL of sterile purified water were added to a 1.5 mL tube and immediately mixed by pipetting. A 1 cm square piece of gauze (Osaki Medical Co., Ltd., "Cross Gauze Cotton No. 6," basis weight: approximately 36 g / m) was placed in a Petri dish. 2 , 100% cotton) was placed in a container, to which 60 μL of the above-mentioned pipetted aqueous solution (cellooligosaccharide concentration 1% (w / v), phosphoric acid concentration 42.5% by mass) was added, and the container was left to stand at room temperature for 2 hours. As a result, CEL-NH2 was precipitated by self-assembly and immobilized on the gauze, yielding CEL-NH2-composite gauze. Here, "% (w / v)" is the mass-volume percent concentration, which is the mass (g) of the target substance contained in a volume of 100 mL.

[0039] ·purification: The CEL-NH2 composite gauze obtained above was placed in a 9 cm Petri dish, and sterilized purified water was added so that the gauze was completely immersed. The gauze was left to stand at room temperature for 1 hour, and then the sterilized purified water was removed. This procedure was repeated five times, and the CEL-NH2 composite gauze was then immersed in D-PBS(-) for 12 hours.

[0040] After purification, the morphology of the CEL-NH2 composite gauze was observed using a scanning electron microscope (SEM) at magnifications of 5,000x and 40,000x. As shown in Figure 4, the CEL-NH2 aggregates were nanoribbon-shaped, and the nanoribbons were immobilized in spikes on the surface of the cellulose fibers of the gauze body. The amount of CEL-NH2 immobilized on the gauze body was 16 parts by mass per 100 parts by mass of the gauze body.

[0041] E. coli adhesion treatment: 1 x 10 cells in a 3cm petri dish 7 Three mL of a D-PBS(-) solution of E. coli (ATCC51813 strain, obtained from Microbiologics) containing colony-forming units (CFU) / mL was added. The CEL-NH2 composite gauze soaked in the purified PBS solution was placed on an autoclave-sterilized paper towel (Kimtowel, manufactured by Nippon Paper Crecia Co., Ltd.) for 5 seconds to absorb water, then placed in a petri dish, immersed in the E. coli / PBS solution, and allowed to stand (incubate) at 37°C for 24 hours.

[0042] Washing: To remove any E. coli bacteria that had not adhered to the gauze after incubation, the gauze was placed in a 3 cm Petri dish together with 3 mL of D-PBS(-) and shaken for 30 minutes (using a small desktop shaker "Wave-RP" manufactured by Taitec Corporation, shaking speed: speed 40). This process was repeated twice.

[0043] Bacterial adhesion assessment: After washing, the gauze was placed on a glass slide, and 20 μL of 6 μmol / L SYTO 9 (ThermFisher Scientific) was added to stain the bacteria green. The gauze was then covered with a cover glass and bacterial adhesion was evaluated using a fluorescence microscope. Images obtained by fluorescence microscopy are shown in Figure 3(A).

[0044] (Example 2: CEL-NH2 composite gauze (neutralization-induced precipitation fixation)) ·Complexation of gauze with cellooligosaccharides: A 1 mol / L aqueous solution of sodium hydroxide was added to the freeze-dried aminated cellooligosaccharide (CEL-NH2) so that the concentration of aminated cellooligosaccharide became 2% (w / v), and the aminated cellooligosaccharide was dissolved. The resulting solution was left to stand at -20°C for 20 minutes and then thawed at 25°C. A 1 cm square piece of gauze (Osaki Medical Co., Ltd., "Cross Gauze Cotton No. 6", basis weight: approximately 36 g / m) was placed in a Petri dish. 2 A 100% cotton gauze was placed in the gauze, and 30 μL of the melted cellooligosaccharide solution (2% (w / v)) was added. 30 μL of 1 mol / L hydrochloric acid / 0.1 mol / L phosphate buffer solution was then added. The gauze was left to stand at room temperature for 1 hour to precipitate aminated cellooligosaccharides by self-assembly. The final self-assembly concentrations were 1% (w / v) for cellooligosaccharides and 0.5 mol / L for NaCl. This immobilized CEL-NH2 on the gauze, yielding CEL-NH2-composite gauze.

[0045] ·purification: The CEL-NH2 composite gauze obtained above was placed in a 9 cm Petri dish, and sterilized purified water was added so that the gauze was completely immersed. The gauze was left to stand at room temperature for 1 hour, and then the sterilized purified water was removed. This procedure was repeated five times, and the CEL-NH2 composite gauze was then immersed in D-PBS(-) for 12 hours.

[0046] After purification, the morphology of the CEL-NH2 composite gauze was observed using a scanning electron microscope (SEM) at magnifications of 5,000x and 40,000x. As shown in Figure 5, the CEL-NH2 aggregates were in the form of nanoribbons, and the nanoribbons were immobilized in a network on the surface of the cellulose fibers of the gauze body. The amount of CEL-NH2 immobilized on the gauze body was 15 parts by mass per 100 parts by mass of the gauze body.

[0047] E. coli adhesion treatment, cleaning, and bacterial adhesion evaluation: The CEL-NH2 composite gauze obtained by the neutralization-induced precipitation fixation described above was subjected to the treatment for attaching Escherichia coli, washed, and the bacterial adhesion evaluation in the same manner as in Example 1. Images obtained by fluorescence microscopy are shown in Figure 3(B).

[0048] (Comparative Example 1: Uncomposite Gauze) 1cm square gauze (Osaki Medical Co., Ltd. "Cross Gauze Cotton No. 6", mesh weight: approx. 36g / m 2 Uncomposite gauze (100% cotton) was used and soaked in D-PBS(-) for 12 hours, and the "E. coli adhesion treatment," "washing," and "bacterial adhesion evaluation" were carried out in the same manner as in Example 1. Images obtained by fluorescence microscopy are shown in Figure 3(C).

[0049] As shown in Figure 3(C), E. coli was sparsely attached to the fiber surface of the uncomposite gauze. In contrast, E. coli was densely attached to the entire gauze fiber of the CEL-NH2 composite gauze (immobilized by phosphoric acid precipitation) of Example 1 shown in Figure 3(A). Similarly to Example 1, E. coli was observed adhering to the entire gauze fiber of the CEL-NH2 composite gauze (immobilized by neutralization-induced precipitation) of Example 2 shown in Figure 3(B). Comparing Example 1 and Example 2, Example 1, which used phosphoric acid precipitation immobilization, showed less variation in the amount of E. coli attached to each fiber. This is presumably because phosphoric acid precipitation immobilization resulted in more uniform immobilization to the cellulose fibers. In Examples 1 and 2 and Comparative Example 1, E. coli was attached to gauze in the absence of serum.

[0050] [Test Example 2] Example 3 The same procedures as in Example 1 ("composite of gauze and cellooligosaccharides," "purification," "treatment for attaching E. coli," and "washing") were carried out to prepare CEL-NH2 composite gauze (immobilized by phosphate precipitation) with E. coli attached. The amount of E. coli attached to the gauze was quantified using the obtained gauze. The details are as follows.

[0051] Quantification of E. coli: One mL of D-PBS(-) solution was added to a 1.5 mL tube, and a washed gauze was placed inside. The tube was then sonicated (25°C, 40 kHz) for 5 minutes to detach the E. coli from the gauze. The PBS solution containing the detached E. coli was serially diluted with D-PBS(-) solution, and 1 mL of the diluted solution was added dropwise to a medium (Shimadzu Diagnostics Co., Ltd., "Compact Dry CF") and incubated at 35°C for 1 day. After incubation, the number of colonies was counted.

[0052] In Example 3, in the E. coli adhesion treatment step, E. coli / PBS solutions were used that did not contain FBS (fetal bovine serum, obtained from Biowest) (0% by mass) and those that contained FBS at concentrations of 1% by mass or 10% by mass, and adhesion treatment was performed for each.

[0053] For comparison, a 1cm square piece of gauze (Osaki Medical Co., Ltd. "Cross Gauze Cotton No. 6", weight: approximately 36g / m 2 Uncomposite gauze (100% cotton) was used and soaked in D-PBS(-) for 12 hours. The other procedures were the same as for the CEL-NH2 composite gauze (phosphate precipitate fixation), and the "E. coli adhesion treatment," "washing," and "E. coli quantification" were carried out.

[0054] Example 4 The same procedures as in Example 2, "complexation of gauze with cellooligosaccharides," "purification," "treatment for attaching E. coli," and "washing," were carried out to prepare CEL-NH2 composite gauze (neutralization-induced precipitation immobilization) with E. coli attached. Using the obtained gauze, the amount of E. coli attached to the gauze was quantified in the same manner as in Example 3. As a control, a 1 cm square piece of gauze ("Cross Gauze Cotton No. 6" manufactured by Osaki Medical Co., Ltd., basis weight: approximately 36 g / m2) was also prepared. 2 Uncomposite gauze (100% cotton) was used and soaked in D-PBS(-) for 12 hours. The other procedures were the same as for the CEL-NH2 composite gauze (neutralization-induced precipitation fixation), and the "E. coli adhesion treatment," "washing," and "E. coli quantification" were carried out.

[0055] The results of Test Example 2 are shown in Figure 6. Figure 6(A) shows the results for the CEL-NH2 composite gauze (immobilized by phosphoric acid precipitation) of Example 3, and Figure 6(B) shows the results for the CEL-NH2 composite gauze (immobilized by neutralization-induced precipitation) of Example 4. In Figure 6, the gauze composited with aminated cellooligosaccharide (CEL-NH2) is indicated as "nano," and the uncomplexed gauze used as a control is indicated as "(-)."

[0056] As shown in Figure 6, the CEL-NH2 complexed gauze of Examples 3 and 4 had a higher amount of E. coli attached to it than the control uncomplexed gauze (-), both in the presence and absence of serum (FBS).

[0057] The various numerical ranges described in this specification can be arbitrarily combined with their upper and lower limits, and all such combinations are considered to be preferred numerical ranges described in this specification. Furthermore, a numerical range described as "X to Y" means from X to Y.

[0058] Although several embodiments of the present invention have been described above, these embodiments are presented as examples and are not intended to limit the scope of the invention. These embodiments can be implemented in various other forms, and various omissions, substitutions, and modifications can be made without departing from the spirit of the invention. These embodiments and their omissions, substitutions, modifications, etc. are included within the scope and spirit of the invention, as well as within the scope of the invention described in the claims and their equivalents.

Claims

1. A medical gauze comprising a gauze body and a cellooligosaccharide having an amino group-containing substituent at the anomeric position of the reducing end and immobilized on the gauze body.

2. The cellooligosaccharide is represented by the following general formula (1): 【Chemistry 1】 In the formula, n represents the average degree of polymerization and is a number from 5 to 20, and A represents a divalent hydrocarbon group having 1 to 20 carbon atoms. The medical gauze according to claim 1.

3. 3. The medical gauze according to claim 1, wherein the cellooligosaccharide is immobilized on the gauze body by precipitation in the presence of the gauze body.

4. 3. The medical gauze according to claim 1, which is used to cover a wound surface.

Images